Abstract:Recent advances in computational methods provide the promise of dramatically accelerating drug discovery. While mathematical modeling and machine learning have become vital in predicting drug-target interactions and properties, there is untapped potential in computational drug discovery due to the vast and complex chemical space. This paper builds on our recently published computational fragment-based drug discovery (FBDD) method called fragment databases from screened ligand drug discovery (FDSL-DD). FDSL-DD uses in silico screening to identify ligands from a vast library, fragmenting them while attaching specific attributes based on predicted binding affinity and interaction with the target subdomain. In this paper, we further propose a two-stage optimization method that utilizes the information from prescreening to optimize computational ligand synthesis. We hypothesize that using prescreening information for optimization shrinks the search space and focuses on promising regions, thereby improving the optimization for candidate ligands. The first optimization stage assembles these fragments into larger compounds using genetic algorithms, followed by a second stage of iterative refinement to produce compounds with enhanced bioactivity. To demonstrate broad applicability, the methodology is demonstrated on three diverse protein targets found in human solid cancers, bacterial antimicrobial resistance, and the SARS-CoV-2 virus. Combined, the proposed FDSL-DD and a two-stage optimization approach yield high-affinity ligand candidates more efficiently than other state-of-the-art computational FBDD methods. We further show that a multiobjective optimization method accounting for drug-likeness can still produce potential candidate ligands with a high binding affinity. Overall, the results demonstrate that integrating detailed chemical information with a constrained search framework can markedly optimize the initial drug discovery process, offering a more precise and efficient route to developing new therapeutics.

Applications of “linkers” in Fragment-Based Drug Design

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Linkers in fragment-based drug design: an overview of the literature

Fragment Databases from Screened Ligands for Drug Discovery (FDSL-DD).

Streamlining Computational Fragment-Based Drug Discovery Through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening

Application of Fragment-Based Drug Discovery to Versatile Targets

Recent progress on fragment-based drug design

Evolutions in Fragment-Based Drug Design: the Deconstruction-Reconstruction Approach.

AutoLinker: Automatic Fragment Linking with Deep Conditional Transformer Neural Networks

DRlinker: Deep Reinforcement Learning for Optimization in Fragment Linking Design

Syntalinker: Automatic Fragment Linking With Deep Conditional Transformer Neural Networks

In silico construction of a focused fragment library facilitating exploration of chemical space**

Computational Fragment-Based Drug Design: Current Trends, Strategies, and Applications

Fragment Informatics and Computational Fragment‐Based Drug Design: an Overview and Update

In silico Strategies to Support Fragment-to-Lead Optimization in Drug Discovery

How to Find a Fragment: Methods for Screening and Validation in Fragment‐Based Drug Dscovery

Novel strategy for three-dimensional fragment-based lead discovery.

A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors

Using DNA-encoded Libraries of Fragments for Hit Discovery of Challenging Therapeutic Targets

Recent Advances in the Linkers of Drug Conjugates

Concepts and Core Principles of Fragment-Based Drug Design